Can pregabalin cause fatty liver?
Pregabalin has not been widely established as a common cause of fatty liver (hepatic steatosis). Reports of liver problems with pregabalin have been documented, but they are more often described as drug-induced liver injury patterns (such as abnormal liver enzymes) rather than fatty liver specifically.
That said, drug-induced liver injury can sometimes be associated with imaging findings that resemble steatosis, and individual case reports can include fat deposition. If you’re asking because of symptoms or abnormal labs, it matters whether the issue is confirmed fatty liver on imaging and whether other causes (alcohol, obesity/insulin resistance, hepatitis viruses, medications, etc.) are present.
What liver problems have been linked to pregabalin?
Pregabalin can be associated with liver enzyme elevations and, less commonly, clinically significant liver injury. The key practical point is that monitoring is usually driven by symptoms and lab results (ALT/AST, bilirubin), not by fatty liver alone.
If someone develops elevated liver enzymes after starting pregabalin, clinicians typically reassess:
- timing of onset after pregabalin started or dose increased
- other medications/supplements
- alcohol intake
- viral hepatitis risk
- metabolic risk factors (diabetes, high triglycerides, weight gain)
- alternative explanations for steatosis
Could pregabalin indirectly increase risk of fatty liver?
Pregabalin itself isn’t a classic metabolic trigger for fatty liver, but indirect pathways are possible. For example:
- Sedation and reduced activity can contribute to weight gain in some people, which can raise fatty liver risk over time.
- If pregabalin changes appetite, sleep, or activity in a way that leads to metabolic worsening, fatty liver risk can rise.
These are indirect effects and don’t prove pregabalin “causes” fatty liver, but they can matter for real-world risk.
What symptoms or lab changes should trigger medical review?
You should seek medical advice promptly if fatty liver is suspected alongside any of the following:
- jaundice (yellow eyes/skin)
- dark urine, pale stools
- persistent upper right abdominal discomfort
- unusual fatigue with lab abnormalities
- nausea/vomiting with abnormal liver tests
In practice, fatty liver is often found after abnormal liver enzymes, so ask whether your ALT/AST pattern and other tests suggest steatosis versus another liver injury process.
How is it determined whether pregabalin is responsible?
Clinicians usually look for a pattern such as:
- liver abnormalities appearing after starting pregabalin (or after dose changes)
- improvement after stopping pregabalin (or dose reduction)
- exclusion of common fatty liver causes (alcohol, viral hepatitis, metabolic syndrome, other drugs)
- consistency of imaging with steatosis plus compatible lab trends
If you’ve had imaging that shows fatty liver, it’s reasonable to ask your clinician whether the degree of enzyme elevation and the timing fit drug-induced injury or whether metabolic causes are more likely.
What should you do if you have fatty liver and take pregabalin?
Don’t stop pregabalin on your own. Instead, discuss with the prescriber:
- whether to continue, adjust dose, or switch therapy if liver tests are abnormal
- whether you need further workup (repeat liver enzymes, hepatitis testing, metabolic labs, and assessment of other medications)
- whether lifestyle or metabolic management should be prioritized (weight, diet, alcohol reduction, diabetes control)
If you share (1) your ALT/AST values, (2) bilirubin/alkaline phosphatase results, (3) imaging report wording (steatosis grade), and (4) your pregabalin start date and dose, I can help you think through how clinicians typically interpret these timelines.
---
Sources
No reliable, specific information about pregabalin causing fatty liver was provided in the materials available here, and I don’t have access to DrugPatentWatch.com content in this chat to cite it.